Pharmacometabolomics of docetaxel-treated human MCF7 breast cancer cells provides evidence of varying cellular responses at high and low doses

Breast Cancer Research and Treatment

Volumn 120, Issue 3, 2010, Pages 613-626

  Bayet Robert, Mathilde ^a   Morvan, Daniel ^a   Chollet, Philippe ^a   Barthomeuf, Chantal ^b  

^a CENTRE JEAN PERRIN   (France)

^b Faculte de Pharmacie   (France)

Author keywords

Adaptive response; Cytotoxicity; Docetaxel; Dose dependence; Glutathione metabolism; MCF7 breast cancer cells; Metabolite kinetics; Pharmacometabolomics; Phospholipid metabolism

Indexed keywords

DOCETAXEL; GLUTATHIONE TRANSFERASE;

ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE ARREST; CELL DEATH; CELL LEVEL; CONTROLLED STUDY; CYTOTOXICITY; DNA CONTENT; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME SYNTHESIS; GLUTATHIONE METABOLISM; GLYCOLYSIS; HUMAN; HUMAN CELL; IC 50; LIPID METABOLISM; METABOLOMICS; MORPHOLOGY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUTATHIONE; HUMANS; METABOLIC NETWORKS AND PATHWAYS; METABOLOMICS; MITOSIS; NEOPLASM PROTEINS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PHOSPHOLIPIDS; TAXOIDS;

EID: 77950867821     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0430-1     Document Type: Article

References (51)

1. Parkin DM (2004) International variation. Oncogene 23:6329-6340. doi : 10.1038/sj.onc.1207726
2. 2. Lacey JV Jr, Devesa SS, Brinton LA (2002) Recent trends in breast cancer incidence and mortality. Environ Mol Mutagen 39: 82-88. doi:10.1002/em.10062 (Pubitemid 34260479)
3. 3. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, Von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 17:2341-2354 (Pubitemid 29368232)
4. 4. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Aapro M et al (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17:1413-1424 (Pubitemid 29220847)
5. 5. Ford HE, Yap YS, Miles DW, Makris A, Hall M, Miller L, Harries M, Smith IE, Johnston SR (2006) A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer. Cancer Chemother Pharmacol 58:809-815. doi: 10.1007/S00280-006-0222-9 (Pubitemid 44351262)
6. Ringel I, Horwitz SB (1991) Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83:288-291. doi:10.1093/jnci/83.4.288
7. 7. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW Jr (2001) The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61:3369-3372 (Pubitemid 32695027)
8. 8. Mhaidat NM, Thorne RF, Zhang XD, Hersey P (2007) Regulation of docetaxel-induced apoptosis of human melanoma cells by different isoforms of protein kinase C. Mol Cancer Res 5:1073-1081. doi: 10.1158/1541-7786.MCR-07-0059 (Pubitemid 350070762)
9. 9. Wang LG, Liu XM, Kreis W, Budman DR (1999) The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 44:355-361. doi:10.1007/s002800050989 (Pubitemid 29455579)
10. 10. Hernandez-Vargas H, Palacios J, Moreno-Bueno G (2007) Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. Oncogene 26: 2902-2913. doi:10.1038/sj. onc1210102 (Pubitemid 46701448)
11. Noguchi S (2006) Predictive factors for response to docetaxel in human breast cancers. Cancer Sci. 97:813-820. doi: 10.1111/j.1349-7006.2006.00265.x
12. 12. Mizumachi T, Suzuki S, Naito A, Carcel-Trullols J, Evans TT, Spring PM, Oridate N, Furuta Y, Fukuda S, Higuchi M (2008) Increased mitochondrial DNA induces acquired docetaxel resistance in head and neck cancer cells. Oncogene 27:831-838. doi: 10.1038/sj.onc,121068l (Pubitemid 351186319)
13. Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ, Pu YS (2005) Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 65:8455-8460. doi: 1.01158/ 0008-5472.CAN-05-1162
14. 14. Alexandre J, Hu Y, Lu W, Pelicano H, Huang P (2007) Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res 67:3512-3517. doi: 10.1158/0008-5472.CAN-06-3914 (Pubitemid 46762129)
15. 15. Oktem G, Karabulut B, Selvi N, Sezgin C, Sanli UA, Uslu R, Yurtseven ME, Omay SB (2004) Differential effects of doxorubicin and docetaxel on nitric oxide production and inducible nitric oxide synthase expression in MCF-7 human breast cancer cells. Oncol Res 14:381-386 (Pubitemid 39070679)
16. 16. Oktem G, Bilir A, Selvi N, Yurtseven ME, Vatansever S, Ates U, Uysal A, Omay SB (2006) Chemotherapy influences inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) activity on 3D breast cancer cell line. Oncol Res 16:195-203 (Pubitemid 44744178)
17. Saito F, Matsusaka S, Takahashi Y, Wakabayashi I (2008) Enhancement of nitric oxide synthase induction in alveolar macrophages by in vivo administration of docetaxel. Eur J Pharmacol 580:425-430. doi: 10.1016/j.ejphar.2007.11.006
18. 18. Maestre N, Bezombes C, Plo I, Levade T, Lavelle F, Laurent G, Jaffrezou JP (2003) Phosphatidylcholine-derived phosphatidic acid and diacylglycerol are involved in the signaling pathways activated by docetaxel. J Exp Ther Oncol 3:36-46. doi: 10.1046/ j.1359-4117.2003.01065.x (Pubitemid 36722860)
19. 19. Torres K, Horwitz SB (1998) Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 58:3620-3626 (Pubitemid 28376560)
20. 20. Hernandez-Vargas H, Palacios J, Moreno-Bueno G (2007) Telling cells how to die: docetaxel therapy in cancer cell lines. Cell Cycle 6:780-783 (Pubitemid 46572613)
21. 21. Morse DL, Gray H, Payne CM, Gillies RJ (2005) Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther 4:1495-1504. doi: 1.01158/1535-7163.MCT-05-0130 (Pubitemid 41556431)
22. 22. Morvan D, Demidem A (2007) Metabolomics by proton nuclear magnetic resonance spectroscopy of the response to chloroethylnitrosourea reveals drug efficacy and tumor adaptive metabolic pathways. Cancer Res 67:2150-2159. doi:1.01158/0008-5472. CAN-06-2346 (Pubitemid 46424234)
23. Rago R, Mitchen J, Wilding G (1990) DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled water. Anal Biochem 191:31-34. doi: 10.1016/0003-2697(90)90382-J
24. Habig WH, Pabst MJ, Jakoby WB (1974) Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 249:7130-7139
25. Morvan D, Demidem A, Guenin S, Madelmont JC (2006) Methionine-dependence phenotype of tumors: metabolite profiling in a melanoma model using L-[methyl-13C] methionine and high-resolution magic angle spinning 1H-13C nuclear magnetic resonance spectroscopy. Magn Reson Med 55:984-996. doi: 10,1002/mrm. 20869
26. 26. Blajeski AL, Kottke TJ, Kaufmann SH (2001) A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines. Exp Cell Res 270:277-288. doi:10.006/excr,2001.5349 (Pubitemid 33030166)
27. 27. Sterin M, Cohen JS, Mardor Y, Berman E, Ringel I (2001) Levels of phospholipid metabolites in breast cancer cells treated with antimitotic drugs: a 31P-magnetic resonance spectroscopy study. Cancer Res 61:7536-7543 (Pubitemid 32995045)
28. 28. Brisdelli F, Iorio E, Knijn A, Ferretti A, Marcheggiani D, Lenti L, Strom R, Podo F, Bozzi A (2003) Two-step formation of 1H NMR visible mobile lipids during apoptosis of paclitaxel-treated K562 cells. Biochem Pharmacol 65:1271-1280. doi:10.1016/ S0006-2952(03)00080-87 (Pubitemid 36407779)
29. 29. Subbaramaiah K, Marmo TP, Dixon DA, Dannenberg AJ (2003) Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR. J Biol Chem 278:37637-37647. doi: 10.1074/jbc.M301481200 (Pubitemid 37175287)
30. Reggiori F, Klionsky DJ (2005) Autophagosomes: biogenesis from scratch? Curr Opin Cell Biol 17:415-422. doi:10.1016/ j.ceb.2005.06.007
31. Morse DL, Raghunand N, Sadarangani P, Murthi S, Job C, Day S, Howison C, Gillies RJ (2007) Response of choline metabolites to docetaxel therapy is quantified in vivo by localized (31)P MRS of human breast cancer xenografts and in vitro by high-resolution (31)P NMR spectroscopy of cell extracts. Magn Reson Med 58:270-280. doi:10.1002/mrm.21333
32. 32. Knijn A, Brisdelli F, Ferretti A, Iorio E, Marcheggiani D, Bozzi A (2005) Metabolic alterations in K562 cells exposed to taxol and tyrphostin AG957: 1H NMR and biochemical studies. Cell Biol Int 29:890-897. doi:10.1016/j.cellbi.2005.07.004 (Pubitemid 41654792)
33. 33. Morvan D, Demidem A, Papon J, De Latour M, Madelmont JC (2002) Melanoma tumors acquire a new phospholipid metabolism phenotype under cystemustine as revealed by high-resolution magic angle spinning proton nuclear magnetic resonance spectroscopy of intact tumor samples. Cancer Res 62:1890-1897 (Pubitemid 34408518)
34. 34. Morvan D, Demidem A, Papon J, Madelmont JC (2003) Quantitative HRMAS proton total correlation spectroscopy applied to cultured melanoma cells treated by chloroethyl nitrosourea: demonstration of phospholipid metabolism alterations. Magn Reson Med 49:241-248. doi: 1.01002/mrm.10368 (Pubitemid 36159860)
35. Williams SN, Anthony ML, Brindle KM (1998) Induction of apoptosis in two mammalian cell lines results in increased levels of fructose-1, 6-bisphosphate and CDP-choline as determined by 31P MRS. Magn Reson Med 40:411-420. doi:10.1002/mrm. 1910400311
36. Taylor MM, Macdonald K, Morris AJ, McMaster CR (2005) Enhanced apoptosis through farnesol inhibition of phospholipase D signal transduction. FEBS J 272:5056-5063. doi:10.1111/ J.1742-4658.2005.04914.X
37. Voziyan PA, Haug JS, Melnykovych G (1995) Mechanism of farnesol cytotoxicity: further evidence for the role of PKCdependent signal transduction in farnesol-induced apoptotic cell death, Biochem Biophys Res Commun 212:479-486. doi :10.1006/ bbrc.1995.1995
38. 38. Griner EM, Kazanietz MG (2007) Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 7:281-294. doi:10.1038/nrc2110 (Pubitemid 46480971)
39. 39. Fujii T, Garcia-Bermejo ML, Bernabo JL, Caamano J, Ohba M, Kuroki T, Li L, Yuspa SH, Kazanietz MG (2000) Involvement of protein kinase C delta (PKCdelta) in phorbol ester-induced apoptosis in LNCaP prostate cancer cells. Lack of proteolytic cleavage of PKCdelta. J Biol Chem 275:7574-7582. doi: 10.1074/ jbc.275.11.7574 (Pubitemid 30159656)
40. 40. Tanaka Y, Gavrielides MV, Mitsuuchi Y, Fujii T, Kazanietz MG (2003) Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem 278:33753-33762. doi: 10.1074/jbc.M30331.3200 (Pubitemid 37553209)
41. 41. Pattingre S, Espert L, Biard-Piechaczyk M, Codogno P (2008) Regulation of macroautophagy by mTOR and Beclin 1 complexes. Biochimie 90:313-323. doi: 10.1016/j.biochi.2007.08.014 (Pubitemid 351181247)
42. Merida I, Avila-Flores A, Merino E (2008) Diacylglycerol kinases: at the hub of cell signalling. Biochem J 409:1-18. doi: 10.1042/ BJ20071040
43. 43. Wright MM, Henneberry AL, Lagace TA, Ridgway ND, McMaster CR (2001) Uncoupling farnesol-induced apoptosis from its inhibition of phosphatidylcholine synthesis. J Biol Chem 276: 25254-25261. doi:10.1074/jbc.M011552200 (Pubitemid 37413009)
44. 44. Ruiz-Arguello MB, Basanez G, Goni FM, Alonso A (1996) Different effects of enzyme-generated ceramides and diacylglycerols in phospholipid membrane fusion and leakage. J Biol Chem 271: 26616-26621. doi:10.1074/jbc.271. 43.26616 (Pubitemid 26359064)
45. Mosharov E, Cranford MR, Banerjee R (2000) The quantitatively important relationship between homocysteine metabolism and glutathione synthesis by the transsulfuration pathway and its regulation by redox changes. Biochemistry 39:13005-13011. doi: 10.1021/bi001088w
46. Prathapasinghe GA, Siow YL, Xu Z, O K (2008) Inhibition of cystathionine-beta-synthase activity during renal ischemiareperfusion: role of pH and nitric oxide. Am J Physiol Renal Physiol 295:F912-F922. doi:10.1152/ajprenal.00040.2008
47. 47. Iwata-Ichikawa E, Kondo Y, Miyazaki I, Asanuma M, Ogawa N (1999) Glial cells protect neurons against oxidative stress via transcriptional up-regulation of the glutathione synthesis. J Neuronem 72:2334-2344. doi: 10.1046/J.1471-4159.1999.0722334.x (Pubitemid 29242183)
48. 48. Perrotta C, De Palma C, Falcone S, Sciorati C, Clementi E (2005) Nitric oxide, ceramide and sphingomyelinase-coupled receptors: a tale of enzymes and messengers coordinating cell death, survival and differentiation. Life Sci 77:1732-1739. doi:10.1016/ j.lfs.2005.05.016 (Pubitemid 41073666)
49. Beddowes EJ, Faux SP, Chipman JK (2003) Chloroform, carbon tetrachloride and glutathione depletion induce secondary genotoxicity in liver cells via oxidative stress. Toxicology 187:101-115. doi: 1.01016/S0300-483X(03)00058-61
50. 50. Demidem A, Morvan D, Madelmont JC (2006) Bystander effects are induced by CENU treatment and associated with altered protein secretory activity of treated tumor cells: a relay for chemotherapy? Int J Cancer 119:992-1004. doi:10.1002/ijc,21761 (Pubitemid 44116905)
51. Ward NE, Pierce DS, Chung SE, Gravitt KR, O'Brian CA (1998) Irreversible inactivation of protein kinase C by glutathione. J Biol Chem 273:12558-12566. doi:10.1074/jbc.273.20.12558